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Abstract Sepsis is life-threating organ dysfunction due to
infection. Incidence of sepsis is increasing and the short-
termmortality is improving, generating more sepsis survivors.
These sepsis survivors suffer from additional morbidities such
as higher risk of readmissions, cardiovascular disease, cogni-
tive impairment and of death, for years following index sepsis
episode. In the first year following index sepsis episode, ap-
proximately 60 % of sepsis survivors have at least one
rehospitalisation episode, which is most often due to infection
and one in six sepsis survivors die. Sepsis survivors also have
a higher risk of cognitive impairment and cardiovascular dis-
ease contributing to the reduced life expectancy seen in this
population, when assessed with life table comparisons. For
optimal design of interventional trials to reduce these bad
outcomes in sepsis survivors, in-depth understanding of major
risk factors for these morbid events, their modifiability and a
causal relationship to the pathobiology of sepsis is essential.
This review highlights the recent advances, clinical and meth-
odological challenges in our understanding of these morbid
events in sepsis survivors.
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Introduction
Sepsis has been redefined recently as life-threatening organ
dysfunction caused by dysregulated host responses to infec-
tion and septic shock as a subset of sepsis in which particularly
profound circulatory, cellular and metabolic abnormalities are
associated with a greater risk of mortality than with sepsis
alone [1, 2].
Globally, sepsis is common, with an estimated population
incidence of 270 (95 % CI 176–412) cases per-100,000
person-years and acute mortality of 26.0 %[3]. A number of
reasons suggest even this underestimates the magnitude of
sepsis associatedmortality andmorbidity. First, as the authors’
of this paper [3] highlight, the incidence data is primarily
critical care based, with limited data from low- and middle-
income-countries. Second, at the bedside, sepsis cases
represent either a new organ dysfunction or worsening of
chronic organ dysfunction such as those seen in comorbid
conditions [1], in the context of suspected or proven infection.
The literature on prevalence of organ dysfunction outside the
critical care environment is limited and when estimated
appears frequently [4]. Alongside this underestimated
incidence globally, the short-term mortality from sepsis is
improving [5, 6]. This epidemiology pattern generates approx-
imately 14 million sepsis survivors globally [3], increasing
yearly, with ongoing health care needs [7].
In this background, after highlighting the conceptual ap-
proach and methodological challenges, this review focuses
on the additional long-term risk of death, readmissions, car-
diovascular disease, cognitive impairment and quality of life
(QOL) alterations in sepsis survivors, followed by a brief
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overview of biological mechanisms contributing to these
outcomes.
Conceptual Approach
Sepsis and the outcomes following sepsis are best conceptu-
alized as consequences of a complex interplay between base-
line characteristics including pre-illness health status, risk fac-
tors for infection, dysregulated immune responses and those
for developing acute organ dysfunction, health care setting,
treatments provided and the response to treatments. The risk
factors for infection include extremes of age, male sex, comor-
bidities, race, genetics, prior sepsis, surgery, any
hospitalisation and frailty [8–16]. There is no accepted defini-
tion for dysregulated immune responses in sepsis [17], the risk
factors for infection highlighted and potentially genetic varia-
tions [18] determine these immune responses. The mecha-
nisms of organ dysfunction in sepsis are still debated [19,
20]; the risk factors for infection and immune responses are
considered risk factors for organ dysfunction. In addition to
short-term outcomes, all these characteristics also influence
the long-term outcomes in sepsis survivors [21–24, 25••].
One of the most important lessons from the last decade of
studying long-term outcomes of sepsis and other critical ill-
nesses is that poor functional status is a risk factor for becom-
ing critically ill as well as a frequent consequence. Similarly,
many comorbidities, age and chronic diseases are risk factors
both for sepsis and for impaired quality of life. Therefore, it is
important in reviewing the literature to distinguish studies that
have tried to separate out the potentially causal effects of sep-
sis from those that simply describe morbidity and mortality
events [25••]. Understanding this fundamental concept helps
to identify risk factors including those that are changeable,
quantify this modifiable risk and target specific interventions
at specific time-points in survivor trajectory to improve health
in sepsis survivors (Fig. 1).
Challenges
There are a number of challenges to studying the potentially
causal post-acute residual effects of sepsis. First, when study-
ing risk factors and assessing modifiable risk, the acute effects
of sepsis have to be separated by specifically looking for in-
dependent associations in the sepsis survivors population as
opposed to the admission cohort with sepsis. Second, dose-
response effect is important for biological plausibility argu-
ments. An increase in sepsis severity may worsen post-acute
sequelae, however, it will also increase the probability of
short-term mortality. Therefore, the competing risk of death
may hide the longer-term non-mortality effects of sepsis.
Third, studies evaluating the long-term outcomes following
sepsis often do not account for pre-illness trajectory. When
this is accounted for, the independent effects of sepsis on
long-term outcomes generate different results [9]. Fourth,
studies without control arms will not provide an estimate of
sepsis attributable risk [25••, 26••] and therefore are of little
value in planning interventions. Fifth, if the long-term out-
come studied cannot be defined for all individuals in a cohort
either due to death or loss to follow-up and this missing data is
differential, bias due to truncation-by-death occurs [27].
Typically, this occurs when evaluating long-term quality
of life in survivors using follow up data from clinical
trials and observational studies, when there is missing
data from those sepsis survivors who die prior to
obtaining a quality of life estimate. In the scenario
where trial data is used, the probability of death in itself
may be altered by the intervention and the baseline
balance of randomisation is lost when assessing survivors. In
observational studies, those survivors with missing data may
be systematically different to those who have follow up data.
Methodological Approaches to Overcome Challenges
There are two ideal study designs to measure the causal effects
of sepsis on long-term outcomes: a yet to be done large cohort
study starting with a healthy population well before index
sepsis episode to understand pre-illness trajectory, then these
patients are followed through after sepsis with detailed mea-
sures of health status, processes of care, and biologic measures
or an impossible controlled trial that randomly induces sepsis.
The available observational studies use alternative methods to
address this question with attendant limitations. To ascertain
the pre-illness trajectory, a health care contact look back could
be done and a look back period between one and 5 years is
considered appropriate [28]. To account for bias secondary to
lack of randomisation, there are numerous methods, the most
well recognised being propensity score based matching. This
approach compares the outcomes of patients who get septic
with controls who were equally likely to get septic but did not
[29]. The principal limitation being unobserved confounders
may vary even after adjustment and matching. When studying
long-term effects of sepsis, there are time-varying con-
founders and mediators such as age, comorbid conditions,
chronic medications, ageing, frailty. Marginal structural
models (MSMs) provide population-averaged causal effects,
which go beyond the statistically independent associations
generated by regression models and post estimation statistics
[30]. Studies without control populations (patients with-
out sepsis as exposure), sepsis attributable risk is imperceptible
and is prone to inference bias if the control population chosen is
not similar to sepsis cohort in all aspects except for the
exposure (sepsis). This important concept is highlighted
using cardiovascular events in sepsis survivors, and it is
this attributable risk is what we hope to reduce using
interventional studies.
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Long-Term Outcomes
Mortality in Sepsis Survivors
Using fundamental principles of causality [31], we recently
reported the limited strength of epidemiological evidence
supporting the premise that sepsis causes an increase in all-
cause mortality after hospital discharge (post-acute mortality)
[25••]. Although the 1-year post-acute mortality was 16.1 %
(95%CI =14.1–18.1 %; N = 43 studies), there was evidence of
statistical and clinical heterogeneity, bias and residual con-
founding. Post-acute mortality was associated with age, male,
co-morbidities, and deterioration in health prior to sepsis.
Since publication of our systematic review, there has been
two further publications [32•, 33•]. The well-conducted study
by Prescott et al. focussed on patients older than 65 years and
used double robust analysis [34] with a regression model for
mortality and propensity score to account for covariates to show
that sepsis is an independent risk factor for post-acute mortality
[32•]. Using propensity score matching, Ou et al. also showed
an increase in all cause mortality in sepsis survivors [33•].
Sepsis associated increased risk of death extends for up to ten
years following index hospitalisation [25••, 32•, 33•, 35].
The magnitude of sepsis-post-acute mortality association
varied dependent on the control population chosen for com-
parison. The additional hazard associated with sepsis was
greatest when compared with general populations [25••].
The magnitude of additional risk of death in sepsis survivors
decreased when the selected control population had more se-
vere non-sepsis illnesses. The major implication being that the
literature currently over estimates the risk of post-acute death
caused by sepsis and therefore preventable fraction is likely to
be lower, which needs to be accounted for during sample size
estimation in future RCTs designed to reduce late mortality in
sepsis survivors.
Rehospitalisation in Sepsis Survivors
Compared to non-sepsis admissions, sepsis survivors had a
greater risk of rehospitalisation [10, 36–38], and rehospitalisation
increases the risk of death. The average 30-day rehospitalisation
rates in sepsis survivors are between 19.9 and 32 % [7, 36–43].
The cumulative rehospitalisation rates increases with follow-up
time with the 90-day and 1-year rehospitalisation rates being
40 % [7, 36] and 63.0 % [7], respectively, implying persistent
risk in sepsis survivors. Pneumonia survivors have lower 30-day
rehospitalisation rates (16.5 % [44] and 18.2 % [45••]), implying
potentially a dose-response effect.
The additional readmissions risk was significantly more
common in sepsis survivors with matched hospitalisations
with acute medical conditions comparisons and a proportion
of these readmissions are potentially preventable [36]. In a
Fig. 1 Conceptual framework for multiple interacting factors influencing
sepsis associated long-term outcomes. The red triangle highlights the
vicious cycle between pre-illness morbidity—sepsis—long-term outcomes
pathway. The arrows represent direction of relationship between factors.
Sepsis occurs in healthy and in subjects with co-morbidities, acutely
altering pre-event health state. Thus, complex interactions between
pre-sepsis health state and additional morbidity and frailty related to sepsis
illness influence post-sepsis health state in sepsis-survivors
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retrospective cohort study, except for parenteral nutrition, the
other risk factors for readmissions identified in univariate
analyses such as transfusion, duration of antibiotics, disap-
peared after regression analyses to account for confounding
[38]. In contrast, 30-day rehospitalisation after sepsis has been
shown to be independently associated included age, malignan-
cy diagnosis, hospitalizations in the year prior to sepsis admis-
sion and low haemoglobin concentrations at discharge [37].
The most common reason for rehospitalisation in sepsis
survivors was infection [46] and infection-related
rehospitalisation represented either unresolved/recurrent in-
fection or new infections [38]. The risk factors and magnitude
of infection-related readmissions differed based on definition
used, implying clinical heterogeneity and confounding by in-
dication in studies. Infection-related rehospitalisation was in-
dependently associated with index admission pathogens (mul-
tidrug resistant pathogens, E. Coli spp. and Bacteroides spp.
infections), renal dysfunction and urinary tract source, with E
Coli spp. and urinary tract being protective [43]. The most
common site in infection-related rehospitalisation in sepsis
survivors was pneumonia, whereas it was urosepsis in non-
sepsis survivor rehospitalisation [46]. In this study, other in-
dependent risk factors for infection-related rehospitalisation
were prolonged hospitalization, age and the presence of an
indwelling catheter [46], implying admission case-mix is an
important determinant for infected-related rehospitalisation in
sepsis survivors.
As with post-acute mortality, further research is required to
understand the true preventable fraction and modifiable risk
factors for rehospitalisation, in particular infection-related
rehospitalisation. Most studies censor death, which is a com-
peting risk factor for readmissions. Independent associations
generated by regression models represent strength of this re-
lationship not a causal pathway, which is yet to be proven. The
dura t ion of addi t iona l r i sk of infec t ion- re la ted
rehospitalisation and the underpinning mechanisms needs to
be further characterised.
Cognitive Impairment in Sepsis Survivors
Hospitalization, regardless of aetiology, is associated with
cognitive decline [47, 48]. The relationship between sepsis
and cognitive decline is likely to be complex and bidirectional
as pre-illness cognitive decline is a risk factor for pneumonia
and sepsis [9, 49, 50••] and sepsis is also an independent risk
factor for cognitive decline (OR 95 % CI 3.3 (1.5–7.3)) [49].
Thus, there is a threefold increase in risk of cognitive decline
in sepsis survivors compared to control populations, but the
rate of new cognitive decline in those sepsis survivors is sim-
ilar to that seen with pre-illness deterioration [49]. Similarly,
pneumonia is associated with cognitive decline and increases
the hazard for dementia (OR 95 % CI 2.2 (1.6–3.6)) [50••].
This hazard ratio does not vary with sepsis severity, implying
no dose response effect [50••]. Depression, which is common
in sepsis survivors, is also a risk factor for pneumonia [51] and
sepsis [52] and is significantly associated with post sepsis
functional impairment [52].
Delirium is common during critical illness, prolongs
hospitalisation and has minimal attributable mortality [53•].
Acute delirium is also associated with cognitive impairment
including dementia and depression during longer-term follow-
up of critical illness survivors [54, 55] and in hospitalised
patients [56]. Sepsis is associated with delirium [57] and
pre-sepsis episode cognitive decline. Thus, the post-sepsis
cognitive decline could either have a causal relationship with
sepsis or could be unrelated to sepsis but acting via the delir-
ium pathway. A related concept that is difficult to test with
new-onset cognitive decline or dementia is the extent of cog-
nitive reserve, whether and how this reserve is modified by
sepsis. This is important as incident cognitive decline is relat-
ed to cognitive reserve and depends on follow-up duration
[58].
Cardiovascular Complications in Sepsis Survivors
In the last 3 years, numerous studies have reported the long-
term risk of cardiovascular events in sepsis survivors.
Corrales-Medina et al. followed two community-based co-
horts (>65 years of age and 45–64 years of age) and assessed
the relationship between index pneumonia episode and subse-
quent cardiovascular disease (CVD) events over a 10-year
period [59]. In this study, CVD events were myocardial in-
farction, stroke and fatal coronary heart disease. The older
cohort had greater CVD events (34.9 % compared to
16.5%). In both cohorts, sepsis was an independent risk factor
for CVD events and the risk was greatest in the year following
index pneumonia episode [59]. Of note, there were residual
imbalances in covariates (e.g. hypertension, diabetes mellitus,
smoking), despite incidence density sampling used to match
cases to controls in this study [59]. Using propensity score
based matching; Yende et al. assessed the independent risk
of cardiovascular events after sepsis as an explanation for long
term increased mortality risk in sepsis survivors [26••]. The
primary outcome was the 1-year incidence rate of hospitalised
cardiovascular events in sepsis survivors. Sepsis survivors had
statistically significant higher rate of cardiovascular events
when compared to propensity matched critically ill,
hospitalised infected controls, and hospitalised non-infected
controls. However, the magnitude of risk attributable to sepsis
was minimal when cardiovascular event risks of acute care
and baseline characteristics were accounted for [26••].
Jafarzadeh et al. assessed the cumulative 5-year risk of cardio-
vascular events in sepsis and used MSMs to generate a causal
inference of additional risk. The odds ratio for sepsis associ-
ated any CVD was 2.39 (1.88–3.03), and there was a dose
response with increase in severity (Bacteremia = 1.52 (1.21–
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1.90); Sepsis = 3.60 (2.59–5.00); and Septic shock = 4.55
(3.58–5.78)). In a community acquired bacteremia cohort
from Denmark with matched general population controls
and hospital controls, Dalager-Pedersen et al. show that the
risk of myocardial infarction is greatest in the first 30-days
following bacteremia. This independent association disap-
pears by 6 months following index bacteremia [60]. Similar
duration of additional risk for CVD events has been reported
in other cohorts [33•, 61].
Quality of Life in Sepsis Survivors
Winters et al. performed a systematic review and identified 12
studies that used different validated tools to assess the QOL in
sepsis survivors, the most common being Short Form 36 (SF-
36) [62]. Overall, sepsis survivors have impaired QOL com-
pared to population norms [62, 63] and this impaired QOL
lasts as long as 5-years after index admission [64]. To account
for pre-illness status and truncation-by-death issues highlight-
ed earlier, Yende et al. used patients enrolled in two
randomised controlled trials and who lived independently pri-
or to the index sepsis episode to show impaired QOL in sepsis
survivors [65]. However, the SF-36 scores in sepsis survivors
were similar to patients with comorbid conditions such as
chronic obstructive pulmonary disease, hypertension and con-
gestive heart failure [66]. Sepsis survivors also have similar
QOL to non-sepsis critically ill survivors [64, 66–68].
Prehospital QOL appears to be an important determinant of
QOL after discharge following hospitalisation and the magni-
tude of additional risk due to critical illness is small compared
to all cause hospitalisations [69]. These observations chal-
lenge a causal inference of sepsis effect on QOL.
Biological Explanations for Long-Term Effects in Sepsis
Survivors
Despite the robustness of statistical methods and independent
associations with some of the long-term outcomes following
sepsis, the epidemiological causality and biological mecha-
nisms are yet to be proven. The cause of death in sepsis sur-
vivors is seldom reported, and the mechanisms leading to
accelerated death in sepsis survivors, if this observation is
causal, are uncertain. Sepsis often occurs in patients with co-
morbid conditions [13, 70], frail and elderly [8]. Many of the
long-term outcomes reported in sepsis survivors are also com-
mon in elderly and frail populations, implying accelerated
ageing could be a potential mechanism. Aging is a multisys-
tem process characterised by cell damage, responses to these
cell damage events and the ensuing phenotype. The cell dam-
age is considered secondary to genomic instability, telomere
attrition and epigenetic alterations [71], which is a nascent
literature in sepsis [72–74]. The cell damage events seen in
aging results in abnormalities of nutrient sensing,
mitochondrial function and cellular senesce [71], some of
which are also seen in sepsis. Ageing results in impaired
lymphopoiesis with relative preservation of myelopoiesis,
with reduction in stem cells. The T cell memory pool is in-
creased, with skewed expansion of CD8 T cells and CD4
differentiation into Th17 population with reduced B cell di-
versity. The lymphocytes from sepsis patients share a number
of these features [75], implying accelerated aging of the im-
mune system in sepsis.
In well-characterised caecal ligation and puncture murine
models of sepsis, sepsis results in sustained central nervous
system inflammation after recovery, which could explain the
long-term cognitive impairments reported [76]. In similar mu-
rine models, elevated serum levels of high mobility group box
1 (HMGB1) was associated with cognitive dysfunction [77]
and is hypothesised to act via the up regulated receptor for
advanced glycation end products (RAGE) [78]. Thus, the hy-
pothesis that neuronal inflammation in sepsis survivors ex-
plains cognitive impairment should be studied. Kaynar et al.
did a RCTusing CLP sepsis models in murines predisposed to
atherosclerosis (ApoE-deficient) and with wild-type mice
[79]. The authors showed that sepsis resulted in persistent
inflammation that predisposes to accelerated atherosclerosis
[79], which provides an explanation for CVS risk in sepsis
survivors in addition to baseline demographic and other risk
factors. In the future, understanding of mechanisms underpin-
ning this accelerated atherosclerosis may identify potential
intervention targets.
Readmissions due to infections in sepsis survivors could be
either due to impaired immune system functions and/or im-
balances in the gastrointestinal microbial flora (dysbiosis) in
sepsis. The acute immune responses in sepsis characterised
using pan leukocyte transcriptome profiles show activation
of pro-inflammatory and anti-inflammatory pathways in the
innate and adaptive immune systems and leaves residual
immunosuppression in sepsis survivors [17, 80–82]. The
mechanisms for post-acute immunosuppression in sepsis
survivors are not well understood. To date, one pilot study
involving just eight patients highlight abnormalities in T cells
and impaired cytokines responses to extrinsic stimuli, long-
after index sepsis episode [83]. Aside from the small sample
size, the variable time interval from index sepsis episode to
immune assessments (between 9 and 60months) and high risk
of bias preclude meaningful inferences. Similar changes were
also observed in splenocytes and lung parenchyma in a land-
mark paper studying deaths from protracted sepsis [84]. A
healthy microbiome consists of obligate anaerobes (e.g.
Bacteroidetes, Firmicutes), and facultative anaerobes (e.g.
Proteobacteria) with diverse with metabolic functions that
maintain check on pathological bacterial density [85–87].
Acute illness, hospitalisation and antibiotics alter this balance
towards a simpler and potentially pathogenic gut bacterial
flora alongside increase in risk for Clostridium Difficile
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infections [87–89]. In a study that did not provide any micro-
biological evidence but presumed dysbiosis based on the
microbiome literature, suggested dysbiosis as a risk factor
for infection related rehospitalisation in sepsis survivors
[10]. Thus, it is valid to hypothesise that both immunosup-
pression and dysbiosis in sepsis survivors potentially contrib-
ute to infection related rehospitalisation. Further studies are
required to confirm these hypotheses.
Conclusions
Sepsis survivors have a different health trajectory prior to and
following their acute illness, but the potentially causal role of
sepsis on the observed long-term impairment and survival re-
mains unclear. For some clinicians and health care administra-
tors, the question of causality is irrelevant. It is a fact that survi-
vors of sepsis, as well as many other acute illnesses requiring
hospitalization, are profoundly functionally impaired and their
health care needs as well as their caregivers’ needs must be
addressed. However, for investigators designing interventions
to prevent or treat these long-term sequelae, a fundamental un-
derstanding of the clinical and biological mechanisms causing
these long-term morbid events in sepsis survivors is required.
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